See more : Novonix Limited (NVNXF) Income Statement Analysis – Financial Results
Complete financial analysis of BriaCell Therapeutics Corp. (BCTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BriaCell Therapeutics Corp., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Naphtha Israel Petroleum Corp. Ltd. (NFTA.TA) Income Statement Analysis – Financial Results
- PT Indonesia Fibreboard Industry Tbk (IFII.JK) Income Statement Analysis – Financial Results
- B-A-L Germany AG (DE000A2NBN90.SG) Income Statement Analysis – Financial Results
- New Dover Capital Corp. (NDVR) Income Statement Analysis – Financial Results
- The Commercial Bank (P.S.Q.C.) (CBQK.QA) Income Statement Analysis – Financial Results
BriaCell Therapeutics Corp. (BCTX)
About BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 82.58K | 15.53K | 15.14K | 15.57K | 13.99K | 14.27K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -82.58K | -15.53K | -15.14K | -15.57K | -13.99K | -14.27K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 26.75M | 15.34M | 8.02M | 1.32M | 2.22M | 3.74M | 2.39M | 1.71M | 723.43K | 105.82K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 6.15M | 7.94M | 7.27M | -3.67M | -1.37M | -932.17K | -1.05M | 876.16K | 942.02K | 1.33M | 436.17K | 423.86K | 556.06K | 1.05M | 323.27K | 203.86K | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | -178.93K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 5.97M | 7.94M | 7.27M | -3.67M | -1.37M | -932.17K | -1.05M | 876.16K | 942.02K | 1.33M | 436.17K | 423.86K | 556.06K | 1.05M | 323.27K | 203.86K | 114.12K | 129.06K | 8.58K |
| Other Expenses | 0.00 | 0.00 | -15.29M | -1.33M | -2.24M | -3.75M | -312.92K | 290.00 | 1.79K | 565.00 | 1.21K | 404.00 | -4.23K | 2.40K | 1.33K | 2.33K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 32.73M | 23.27M | -3.39K | -3.69M | -1.38M | -946.42K | -1.07M | 2.58M | 1.67M | 1.44M | 437.27K | 424.26K | 551.84K | 1.05M | 324.57K | 233.87K | 114.12K | 129.06K | 8.58K |
| Cost & Expenses | 32.81M | 23.27M | -3.39K | -3.69M | -1.38M | -946.42K | -1.07M | 2.58M | 1.67M | 1.44M | 437.27K | 424.26K | 551.84K | 1.05M | 324.57K | 233.87K | 114.12K | 129.06K | 8.58K |
| Interest Income | 0.00 | 891.21K | 136.73K | 3.15K | 39.48 | 9.13K | 12.27K | 5.16K | 3.63K | 7.09K | 12.00K | 16.90K | 38.01K | 13.36K | 2.90K | 2.73K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 979.00 | 46.10K | 27.00K | 23.82K | 15.63K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 82.58K | 15.27K | 15.27K | 15.26K | 15.26K | 14.25K | 12.97K | 232.68 | 907.21 | 434.31 | 1.11K | 392.08 | 1.72K | 2.51K | 1.29K | 154.20 | 12.72K | 5.10K | -1.13K |
| EBITDA | -4.77M | -30.67M | -15.13M | -8.69M | -3.97M | -6.67M | -4.96M | -3.22M | -2.18M | -1.80M | -2.61K | -462.53K | -68.23K | -1.01M | 255.79K | -233.72K | -114.12K | -129.06K | -8.58K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -32.81M | -23.27M | -15.29M | 3.69M | 1.38M | 946.42K | -3.82M | -2.58M | -1.67M | -1.44M | -437.27K | -424.26K | -1.20M | -1.05M | -324.57K | -233.87K | -114.12K | -129.06K | -8.58K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 28.02M | 2.97M | 3.74M | -6.84M | -85.10K | 0.00 | -1.59M | 634.11K | 481.60K | -1.24M | -7.71M | 55.56K | 202.71K | -37.17K | -595.34K | 2.51K | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -4.79M | -20.30M | -11.55M | 3.69M | 1.38M | 946.42K | 1.07M | -2.58M | -1.70M | -2.68M | -8.15M | -368.69K | -995.72K | -1.09M | -919.91K | -231.36K | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 62.85K | -152.62K | 30.73K | 6.58M | -72.25K | 343.74K | 1.59M | 638.59K | 547.97K | 2.05M | 8.45M | -44.35K | -200.92K | -24.03K | 601.48K | 12.46K | -12.72K | -5.10K | 1.13K |
| Net Income | -4.79M | -20.30M | -11.58M | -2.89M | 1.38M | 602.68K | 1.07M | -2.58M | -1.70M | -2.68M | -8.15M | -368.69K | -995.72K | -1.08M | -900.74K | -228.81K | -98.93K | -116.41K | -8.58K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.29 | -1.30 | -0.75 | -0.64 | 1.94 | 1.04 | 2.49 | -7.61 | -5.88 | -10.76 | -138.07 | -6.25 | -16.93 | -33.02 | -49.58 | -25.62 | -20.45 | -27.92 | -4.18 |
| EPS Diluted | -0.29 | -1.30 | -0.75 | -0.64 | 1.94 | 1.04 | 2.49 | -7.32 | -5.88 | -10.76 | -138.07 | -6.25 | -16.93 | -33.02 | -49.58 | -25.62 | -20.45 | -27.92 | -4.18 |
| Weighted Avg Shares Out | 16.45M | 15.62M | 15.49M | 4.52M | 713.89K | 579.66K | 427.81K | 339.71K | 288.44K | 249.18K | 59.00K | 59.00K | 58.83K | 32.67K | 18.17K | 8.93K | 4.84K | 4.17K | 2.05K |
| Weighted Avg Shares Out (Dil) | 16.45M | 15.62M | 15.49M | 4.52M | 713.89K | 579.66K | 427.82K | 352.98K | 288.44K | 249.18K | 59.00K | 59.00K | 58.83K | 32.67K | 18.17K | 8.93K | 4.84K | 4.17K | 2.05K |
BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting
BERKELEY, Calif. and VANCOUVER, British Columbia, May 19, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce the...
BriaCell Announces Investor and Media Outreach Programs
BERKELEY, Calif. and VANCOUVER, British Columbia, April 15, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, announces that it has recently...
BriaCell Announces Closing of Over-Allotment Option in Connection with U.S. Public Offering, Bringing Total Gross Proceeds to US$28.7 Million
BERKELEY, Calif. and VANCOUVER, British Columbia, April 12, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, today announced that it has...
BriaCell Stock Is Trading Higher After Encouraging Bria-IMT Data At AACR Annual Meeting
BriaCell Therapeutics Corp (NASDAQ: BCTX) has announced the presentation of results from clinical studies evaluating its lead product candidate, Bria-IMT, at the American Association for Cancer Research (AACR) Annual Meeting 2021. The findings indicate disease control in advanced breast cancer patients, including stable disease...
BriaCell Therapeutics Presents Clinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2021
Clinical and pathological data presented from the clinical trials of Bria-IMT™ alone and in combination with immune checkpoint inhibitors in advanced breast cancer indicates high responding subset with protracted progression-free survival:
BCTX Stock: Over 10% Increase Pre-Market Explanation
The stock price of Briacell Therapeutics Corp (NASDAQ: BCTX) increased by over 10% pre-market. This is why it happened.
BCTX Stock Price Increases Over 25% Pre-Market: Why It Happened
The stock price of BriaCell Therapeutics Corp. (TSX-V:BCT) (NASDAQ: BCTX, BCTXW) is trading at over 25% pre-market. This is why it happened.
Source: https://incomestatements.info
Category: Stock Reports